1. Home
  2. IHD vs GNLX Comparison

IHD vs GNLX Comparison

Compare IHD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IHD
  • GNLX
  • Stock Information
  • Founded
  • IHD 2011
  • GNLX 2001
  • Country
  • IHD United States
  • GNLX United States
  • Employees
  • IHD N/A
  • GNLX N/A
  • Industry
  • IHD Investment Managers
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IHD Finance
  • GNLX Health Care
  • Exchange
  • IHD Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • IHD 89.7M
  • GNLX 85.0M
  • IPO Year
  • IHD N/A
  • GNLX 2023
  • Fundamental
  • Price
  • IHD $5.24
  • GNLX $5.46
  • Analyst Decision
  • IHD
  • GNLX Strong Buy
  • Analyst Count
  • IHD 0
  • GNLX 4
  • Target Price
  • IHD N/A
  • GNLX $18.25
  • AVG Volume (30 Days)
  • IHD 27.7K
  • GNLX 382.1K
  • Earning Date
  • IHD 01-01-0001
  • GNLX 03-31-2025
  • Dividend Yield
  • IHD 10.32%
  • GNLX N/A
  • EPS Growth
  • IHD N/A
  • GNLX N/A
  • EPS
  • IHD N/A
  • GNLX N/A
  • Revenue
  • IHD N/A
  • GNLX $8,000.00
  • Revenue This Year
  • IHD N/A
  • GNLX N/A
  • Revenue Next Year
  • IHD N/A
  • GNLX N/A
  • P/E Ratio
  • IHD N/A
  • GNLX N/A
  • Revenue Growth
  • IHD N/A
  • GNLX N/A
  • 52 Week Low
  • IHD $4.49
  • GNLX $1.60
  • 52 Week High
  • IHD $5.47
  • GNLX $8.67
  • Technical
  • Relative Strength Index (RSI)
  • IHD 58.24
  • GNLX 75.73
  • Support Level
  • IHD $5.11
  • GNLX $4.10
  • Resistance Level
  • IHD $5.27
  • GNLX $5.89
  • Average True Range (ATR)
  • IHD 0.06
  • GNLX 0.58
  • MACD
  • IHD 0.01
  • GNLX 0.16
  • Stochastic Oscillator
  • IHD 85.71
  • GNLX 84.17

About IHD Voya Emerging Markets High Income Dividend Equity Fund

Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: